OTCPK:LMSM.F

Stock Analysis Report

Executive Summary

Maclos Capital Inc. does not have significant operations.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • Maclos Capital has significant price volatility in the past 3 months.
  • Maclos Capital's last earnings update was 201 days ago.
  • Maclos Capital is not covered by any analysts.

Share Price & News

How has Maclos Capital's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-43.0%

LMSM.F

2.5%

US Healthcare Services

-0.6%

US Market


1 Year Return

-91.2%

LMSM.F

10.2%

US Healthcare Services

0.7%

US Market

LMSM.F underperformed the Healthcare Services industry which returned 10.3% over the past year.

LMSM.F underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

LMSM.FIndustryMarket
7 Day-43.0%2.5%-0.6%
30 Day-85.8%-1.9%2.9%
90 Day-71.5%-2.9%1.3%
1 Year-91.2%-91.2%10.3%10.2%2.9%0.7%
3 Year-36.7%-36.7%51.7%51.4%44.6%35.2%
5 Year-96.2%-96.2%52.0%51.1%61.9%44.2%

Price Volatility Vs. Market

How volatile is Maclos Capital's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Maclos Capital undervalued based on future cash flows and its price relative to the stock market?

0.73x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Maclos Capital to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Maclos Capital to establish if it is available at substantial discount.


Price Based on Earnings

Maclos Capital is loss making, we can't compare its value to the US Healthcare Services industry average.

Maclos Capital is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Maclos Capital, we can't assess if its growth is good value.


Price Based on Value of Assets

Maclos Capital is good value based on assets compared to the US Healthcare Services industry average.


Next Steps

Future Growth

How is Maclos Capital expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Maclos Capital has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Maclos Capital performed over the past 5 years?

-28.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Maclos Capital does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Maclos Capital's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Maclos Capital's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Maclos Capital has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Maclos Capital has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Maclos Capital improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Maclos Capital's financial position?


Financial Position Analysis

Maclos Capital is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Maclos Capital has no long term commitments.


Debt to Equity History and Analysis

Maclos Capital has no debt.

Maclos Capital has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Maclos Capital has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Maclos Capital has sufficient cash runway for more than 3 years based on current free cash flow.

Maclos Capital has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -10.3% each year.


Next Steps

Dividend

What is Maclos Capital's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Maclos Capital's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Maclos Capital's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Maclos Capital has not reported any payouts.

Unable to verify if Maclos Capital's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Maclos Capital has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Maclos Capital's salary, the management and board of directors tenure and is there insider trading?


CEO

Cameron Prange (64yo)

8.7yrs

Tenure

0

Mr. Cameron R. Prange has been Chief Executive Officer and Chief Financial Officer of Maclos Capital, Inc. (formerly LMS Medical Systems Inc.) since January 1, 2011. Mr. Prange serves as President of Kings ...


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Cameron Prange (64yo)

    CEO, CFO & Director

    • Tenure: 8.7yrs
  • Yves Grou (64yo)

    Executive Vice Chairman

    • Tenure: 0yrs
  • Henry Lerner

    Head of Clinical Development

    • Tenure: 0yrs

Board Members

  • Cameron Prange (64yo)

    CEO, CFO & Director

    • Tenure: 8.7yrs
  • Yves Grou (64yo)

    Executive Vice Chairman

    • Tenure: 0yrs
  • Solomon Bierbrier (90yo)

    Independent Director

    • Tenure: 9.7yrs

Company Information

Maclos Capital Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Maclos Capital Inc.
  • Ticker: LMSM.F
  • Exchange: OTCPK
  • Founded: 1993
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$150.839k
  • Shares outstanding: 26.46m
  • Website: https://null

Location

  • Maclos Capital Inc.
  • 181 Bay Street
  • Suite 4400
  • Toronto
  • Ontario
  • M5J 2T3
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LMSM.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDFeb 2004

Biography

Maclos Capital Inc. does not have significant operations. The company intends to identify and evaluate assets or businesses with a view to potentially acquiring them or acquiring an interest therein. Previ ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 23:49
End of Day Share Price2019/09/17 00:00
Earnings2018/12/31
Annual Earnings2018/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.